Andrew D. Smith


Traina Helps Navigate Surge of New Breast Cancer Therapies

September 14th 2020

Nearly 15 years have passed since pathologists at Memorial Sloan Kettering Cancer Center conducted gene expression analyses on breast cancer primary tumors and described a potential role for a novel target, which quickly became a major research focus for their colleague Tiffany A. Traina, MD.

A Myeloma Pioneer Sees More Innovation

March 16th 2020

Kenneth C. Anderson, MD, discusses key trials in multiple myeloma that have reported promising findings or are poised to shed light on novel treatments.

The New Horizon in Melanoma

December 11th 2019

Jeffrey S. Weber, MD, PhD, looks to earlier use of immunotherapy and novel combinations in melanoma.

Shaping the Future in Lung Cancer

November 13th 2019

Rapid advancements are dramatically changing the lung cancer treatment landscape, creating challenges across the spectrum of care.

Novel Metastatic Strategies Gain Traction

October 15th 2019

Emboldened by strong evidence investigators are growing confident that localized therapy in oligometastatic disease across cancers may soon lead to a new staging system and become standard of care.

The New Ovarian Cancer Landscape: Many Questions, Much Hope

September 3rd 2019

In the past 5 years, the FDA has awarded 4 drugs 9 new indications for the treatment of advanced ovarian cancers. Although these approvals represent a welcome expansion of the therapeutic toolkit for this challenging malignancy, the arrival of new options has outpaced efforts to discover the best use for each medication.

Expert Advocates Universal Genetic Testing in Breast Cancer

August 5th 2019

Although research findings have established many applications for genetic information in breast cancer, not enough patients are being tested for the risk of germline mutations and new strategies are needed to broaden the clinical application of genomic advancements.

Fresh Signs of Progress Surface in Geriatric Oncology

August 2nd 2019

Although there has been significant progress in the field of geriatric oncology, experts say there is still a pressing need to increase clinical trial participation by older patients and to improve the predictive value of assessment tools.

The Fight to Save the Bladder Turns to Genomics

June 14th 2019

The search for effective alternatives to radical cystectomy (RC) in patients with bladder cancer has lasted more than 3 decades. Progress has been slow, but investigators have proved that a combination of radiation, chemotherapy, and maximal transurethral resection of the bladder tumor works as well as RC in carefully selected patients.

Persistent BCG Shortages Lead to Hard Choices in Bladder Cancer

April 27th 2019

The Tice strain of BCG has emerged as a go-to drug for treating primary and recurrent bladder cancer, but in the United States and some other countries, a constellation of marketplace dynamics has reduced manufacturers of this agent to a sole producer that is unable to keep up with demand. Available supplies are being rationed, and sufficient expansion of supply could be years away.